The content on this site is intended for healthcare professionals only
Prof Byoung Chul Cho speaks to ecancer at ESMO 2019 in Barcelona about the phase III ATTRACTION-3 study comparing nivolumab with chemotherapy in patients with advanced oesophageal squamous cell carcinoma (ESCC).
He explains that for patients with ESCC who have progressed on platinum based combination chemotherapy there is virtually no option in the second line setting.
He reports that the study demonstrated that nivolumab showed a superior efficacy with manageable toxicities compared to chemotherapy.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
Understanding the remaining unmet needs in a post ASCT NDMM setting
ASCO 2024: Lung cancer highlights
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
OncoAlert round up July 28th to August 3rd, 2023
ATTRACTION-5: Nivolumab plus chemotherapy as postoperative adjuvant treatment for pStage III G/GEJ cancer
Targeting BRAF V600E in metastatic colorectal cancer: where are we today?
NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy in locally advanced rectal cancer
NIVO + chemo and NIVO + IPI continue to demonstrate clinically meaningful survival benefit vs chemo for advanced ESCC
Polatuzumab vedotin combined with R-ICE as second-line therapy gives favourable results against R/R diffuse large B-cell lymphoma
